All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site aml-hub.com.
2020-09-28T15:53:07.000Z

What are the new approaches for anemia in MDS?

Sep 28, 2020
Share:

Bookmark this article

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the new approaches for anemia in MDS.

What are the new approaches for anemia in MDS?

Anemia is one of the predominant clinical features of MDS. Standard of care includes erythropoiesis-stimulating agents to which around 40% of patients respond, leaving a large proportion of patients refractory to treatment. Uwe Platzbecker outlines the major clinical needs in this subset of patients and discusses alternative novel approaches to treating anemia in MDS.

Newsletter

Subscribe to get the best content related to MDS delivered to your inbox